Indeed, ESR1 has been identified as a crucial biomarker of metastatic progression in patients with metastatic estrogen receptor-positive breast cancer, which gives a mechanism of resistance in patients treated with aromatase inhibitors [58]. Here, CYP19A1 is linked to breast cancer.